April 1, 1982Clinical Pharmacology & Therapeutics
Hemodynamic effects of N-acetylprocainamide in heart disease
Key result
Oral and IV N-acetylprocainamide shows no effect on hemodynamics in normal subjects or cardiac patients.
- n=17
Why the study?
The hemodynamic effects of N-acetylprocainamide (NAPA) in patients with heart disease and normal subjects were not well characterized.
Does N-acetylprocainamide affect hemodynamic parameters in normal subjects and patients with heart disease?
Population
6 normal subjects, 6 patients with primary cardiomyopathy, and 5 patients with ventricular dysrhythmias due to cardiac diseases
Comparison
Oral NAPA at 3, 4, 5, and 6 gm/day vs intravenous NAPA infusion
Design
Case series
Follow-up
4 days oral administration or 48 hours intravenous infusion
Authors
Discussion
Loading...
Member takes
Implication
Suggests hemodynamic neutrality in cardiac disease; leaves open randomized trials before any practice consideration.
Structured PICO
Does N-acetylprocainamide affect hemodynamic parameters in normal subjects and patients with heart disease?
P
Population
17 participants, including 6 normal subjects and 11 patients with cardiac disease, evaluated for hemodynamic responses to oral and intravenous N-acetylprocainamide.
I
Intervention
N-acetylprocainamide (NAPA) administered orally (3, 4, 5, and 6 gm/day for 4 days) or intravenously (initial infusion to control dysrhythmias followed by 48-hour maintenance infusion).
O
Outcome
Hemodynamic effects (heart rate, blood pressure, echocardiographic performance indices, pulmonary artery pressures, cardiac output) and dysrhythmia control.surrogate
N-acetylprocainamide appears hemodynamically safe for use in patients with reduced left ventricular performance due to cardiac disease.
Cite This Study
Crawford et al. (1982) studied Heart disease (primary cardiomyopathy, ventricular dysrhythmias) (n=17). N-acetylprocainamide (NAPA) was evaluated on Hemodynamic parameters (heart rate, blood pressure, echocardiographic indices, pulmonary pressures, cardiac output). Oral and intravenous N-acetylprocainamide demonstrated no significant effect on heart rate, blood pressure, or other hemodynamic indices in normal subjects or patients with cardiac disease.